Principal Financial Group
KLRS

Principal Financial Group’s Kalaris Therapeutics KLRS Stock Holding History

Principal Financial Group’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-901
Closed -$15.7K – 2480
2024
Q1 		$15.7K Sell
901
-96
-10% -$1.57K ﹤0.01% 2415
2023
Q4 		$15.6K Sell
997
-110
-10% -$4.34K ﹤0.01% 2393
2023
Q3 		$54.8K Buy
1,107
+115
+12% +$7.84K ﹤0.01% 2340
2023
Q2 		$77.6K Buy
992
+231
+30% +$22K ﹤0.01% 2323
2023
Q1 		$68.9K Buy
761
+10
+1% +$1.27K ﹤0.01% 2346
2022
Q4 		$88.6K Buy
+751
New +$127K ﹤0.01% 2313

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Principal Financial Group's KLRS Position: Q2 2024 in Review

Principal Financial Group sold out of Kalaris Therapeutics (KLRS) in Q2 2024, closing a stake of 901 shares — an estimated $15.7K sold.

Principal Financial Group first reported a position in KLRS in Q4 2022 and held it in 6 quarters. The position peaked at $88.6K in Q4 2022. 71 funds tracked by Wall St. Rank hold KLRS as of Q2 2024.

  • Principal Financial Group reported no remaining Kalaris Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Principal Financial Group sold 901 Kalaris Therapeutics shares in Q2 2024, an estimated $15.7K.
  • Principal Financial Group first reported a position in Kalaris Therapeutics in Q4 2022 and held it in 6 quarters.
  • Principal Financial Group's Kalaris Therapeutics position peaked at $88.6K in Q4 2022.
  • 71 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2024.

Based on Principal Financial Group's 13F filing for Q2 2024, filed 29 Jul 2024.